Lacosamide Zentiva

Lacosamide, the active ingredient in Lacosamide Zentiva, is a sodium channel blocker presented as an oral tablet for oral use. It is used as adjunctive therapy in patients with partial‑onset seizures and other forms of epilepsy.

GNH USA supplies Lacosamide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an antiepileptic drug that works on neuronal sodium channels to control seizure activity.

- Partial‑onset seizures: reduces seizure frequency when added to existing therapy. - Focal seizures: provides adjunctive control in patients not fully managed by other agents. - Epilepsy: serves as an additional option for patients with refractory epilepsy.

Lacosamide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Fatigue: persistent tiredness or lack of energy. - Nausea: upset stomach often accompanied by an urge to vomit. - Headache: mild to moderate pain in the head region. - Blurred vision: temporary visual disturbances. - Diplopia: double vision in some patients.

Serious or Rare Side Effects: - Suicidal thoughts: emergence of depressive symptoms or suicidal ideation. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac arrhythmia: abnormal heart rhythms, including PR‑interval prolongation. - Respiratory depression: slowed breathing, especially when combined with other CNS depressants. - Hypersensitivity: rash, itching, or swelling indicating an allergic response. - Liver injury: elevated liver enzymes or hepatitis in rare cases.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential risks.

- Renal function assessment: adjust dosing in patients with impaired kidney function. - Cardiac monitoring: observe ECG for PR‑interval changes, especially in patients with pre‑existing heart disease. - Concomitant CNS depressants: use caution when combined with alcohol, opioids, or other sedatives. - Hepatic impairment: consider dose modification in patients with liver disease. - Discontinuation: avoid abrupt cessation to reduce seizure recurrence risk. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lacosamide can interact with several medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lacosamide plasma levels. - Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce lacosamide effectiveness. - Other sodium‑channel blockers (e.g., phenytoin, carbamazepine): may enhance central nervous system depression.

Moderate Interactions (Monitor Closely): - Alcohol: can potentiate dizziness and sedation. - Opioids: increased risk of respiratory depression. - Antihistamines: may augment dizziness or visual disturbances. - Valproate: potential additive effect on hepatic enzymes. - Antidepressants (e.g., SSRIs): monitor for mood changes or suicidal thoughts.